Developmental expression of cytochrome P450 enzymes in human liver

被引:95
作者
Hakkola, J
Tanaka, E
Pelkonen, O
机构
[1] Oulu Univ, Dept Pharmacol & Toxicol, FIN-90220 Oulu, Finland
[2] Univ Tsukuba, Inst Community Med, Tsukuba, Ibaraki 305, Japan
来源
PHARMACOLOGY & TOXICOLOGY | 1998年 / 82卷 / 05期
关键词
D O I
10.1111/j.1600-0773.1998.tb01427.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-metabolizing cytochrome P450 enzymes, the major phase I enzymes, are active in human liver already at very early stages of intrauterine development, although presumably at fairly low concentrations and in low numbers. During maturation, these enzymes go through various developmental programmes towards adulthood. The major increase both in abundance as well as in number of different enzymes takes place after birth, probably during the first year of life. Detailed information concerning these developmental changes is still limited. The major drug-metabolizing P450 enzymes appear to be primarily members of the CYP3A subfamily in all stages of development. The balance between different members of this subfamily however, undergoes significant switches from the foetal predominant CYP3A7 to the major adult form CYP3A4. The ontogeny of the other cytochrome P450 enzymes is less well characterized, but the major switch-on appears to occur mainly after birth. Developmental expression of P450 enzymes is one of the key factors determining the pharmacokinetic status of developing individuals both pre-and postnatally.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 84 条
[1]   EFFICACY OF CAFFEINE IN TREATMENT OF APNEA IN LOW-BIRTH-WEIGHT INFANT [J].
ARANDA, JV ;
GORMAN, W ;
BERGSTEINSSON, H ;
GUNN, T .
JOURNAL OF PEDIATRICS, 1977, 90 (03) :467-472
[2]   THE ROLE OF THERAPEUTIC DRUG-MONITORING IN CHILDREN [J].
BOREUS, LO .
CLINICAL PHARMACOKINETICS, 1989, 17 :4-12
[3]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[4]  
Carpenter SP, 1996, MOL PHARMACOL, V49, P260
[5]   MATURATION OF CAFFEINE METABOLIC PATHWAYS IN INFANCY [J].
CARRIER, O ;
PONS, G ;
REY, E ;
RICHARD, MO ;
MORAN, C ;
BADOUAL, J ;
OLIVE, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :145-151
[6]   BIOTRANSFORMATION OF CAFFEINE IN HUMAN LIVER-MICROSOMES FROM FETUSES, NEONATES, INFANTS AND ADULTS [J].
CAZENEUVE, C ;
PONS, G ;
REY, E ;
TRELUYER, JM ;
CRESTEIL, T ;
THIROUX, G ;
DATHIS, P ;
OLIVE, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (05) :405-412
[7]   IMMUNOQUANTIFICATION OF EPOXIDE HYDROLASE AND CYTOCHROME-P-450 ISOZYMES IN FETAL AND ADULT HUMAN-LIVER MICROSOMES [J].
CRESTEIL, T ;
BEAUNE, P ;
KREMERS, P ;
CELIER, C ;
GUENGERICH, FP ;
LEROUX, JP .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1985, 151 (02) :345-350
[8]   AGE-RELATED DIFFERENCES IN HEPATIC DRUG CLEARANCE IN CHILDREN - STUDIES WITH LORAZEPAM AND ANTIPYRINE [J].
CROM, WR ;
RELLING, MV ;
CHRISTENSEN, ML ;
RIVERA, GK ;
EVANS, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (02) :132-140
[9]   PHARMACOKINETICS IN THE CHILD [J].
CROM, WR .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 :111-117
[10]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201